MedTrace Logo

TAP Block With Liposomal Bupivacaine Versus Pre-incisional Wound Infiltration With Bupivacaine for Postoperative Pain

NCT02400645 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2020-04-28

No results posted yet for this study

Summary

In this randomized, controlled, double-blinded trial we plan to evaluate post-operative pain relief after laparoscopic-assisted Transversus Abdominis Plane (TAP) block using liposomal bupivacaine plus bupivacaine versus pre-incisional would infiltration with bupivacaine in patients undergoing Total laparoscopic or robotic assisted laparoscopic hysterectomy.

Conditions

  • Postoperative Pain

Interventions

PROCEDURE

Pre-incisional wound infiltration

Intraoperative: Pre-incisional bupivacaine 0.25% up to 20 cc divided dose for trocar incisions

PROCEDURE

Laparoscope to place TAP block with liposomal bupivacaine

Intraoperative: Laparoscopic TAP block with Liposomal bupivacaine and bupivacaine 0.25%

DRUG

Liposomal bupivacaine

Use of Liposomal bupivacaine in laparoscopic TAP block

DRUG

Bupivacaine

20 cc Bupivacaine 0.25% plain will be used for either pre-incisional injection or added to laparoscopic TAP block solution.

DRUG

Ketorolac

Ketorolac 30mg to be given IV at end of surgical procedure unless contraindicated.

Sponsors & Collaborators

  • University of Tennessee

    lead OTHER

Principal Investigators

  • Shanti I Mohling, MD · University of Tennessee

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-05-31
Completion
2016-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02400645 on ClinicalTrials.gov